CervoMed Inc.
Datakwaliteit: 100%
CRVO
Nasdaq
Manufacturing
Chemicals
€ 4,00
▼
€ 0,04
(-0,99%)
Marktkapitalisatie: 37,03 M
Prijs
€ 4,00
Marktkapitalisatie
37,03 M
Dagbereik
€ 3,91 — € 4,11
52-Weeksbereik
€ 3,51 — € 13,13
Volume
24.024
Openen € 4,03
50D / 200D Gem.
€ 4,55
12,01% below
50D / 200D Gem.
€ 7,24
44,73% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -23,45 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)-58,86%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-90,72%
Onder sectorgemiddelde (-53,41%)
ROIC-65,08%
Net Margin-673,06%
Op. Margin-706,22%
Veiligheid
Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A
Waardering
PE (TTM)
-1,37
Boven sectorgemiddelde (-1,48)
P/B Ratio1,42
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -1,4 | -1,5 |
| P/B | 1,4 | 1,6 |
| ROE % | -90,7 | -53,4 |
| Net Margin % | -673,1 | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
ETFs Holding This Stock
0,00% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -58,86% | Revenue Growth (3Y) | -25,12% |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 4,01 M | Net Income (TTM) | -26,97 M |
| ROE | -90,72% | ROA | -78,51% |
| Gross Margin | N/A | Operating Margin | -706,22% |
| Net Margin | -673,06% | Free Cash Flow (TTM) | -23,45 M |
| ROIC | -65,08% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | N/A |
| Interest Coverage | N/A | Asset Turnover | 0,12 |
| Working Capital | N/A | Tangible Book Value | 26,01 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1,37 | Forward P/E | N/A |
| P/B Ratio | 1,42 | P/S Ratio | 9,24 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -63,32% | ||
| Market Cap | 37,03 M | Enterprise Value | 27,60 M |
| Per Share | |||
| EPS (Diluted TTM) | N/A | Revenue / Share | 0,43 |
| FCF / Share | -2,53 | OCF / Share | -2,53 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 86,96% |
| SBC-Adj. FCF | -24,87 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 4,01 M | 9,74 M | 7,14 M | — | — |
| Net Income | -26,97 M | -16,29 M | -2,17 M | -15,59 M | -24,10 M |
| EPS (Diluted) | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -28,29 M | -18,23 M | -7,81 M | -15,97 M | -24,68 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 21,82 M | 18,80 M | 8,44 M | 7,24 M | 8,50 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | 0,0 | 93.416,0 |
| Interest Expense | — | — | 0,0 | — | — |
| Income Tax | 0,0 | — | — | 0,0 | -443.893,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 22,88 M | 43,08 M | 9,97 M | 22,64 M | 37,84 M |
| Total Liabilities | 4,66 M | 3,88 M | 2,60 M | 2,42 M | 2,93 M |
| Shareholders' Equity | 18,22 M | 39,20 M | 7,38 M | 20,22 M | 34,91 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 8,24 M | 9,00 M | 7,79 M | 10,11 M | 37,31 M |
| Current Assets | 22,88 M | 43,08 M | 9,96 M | 22,64 M | 37,82 M |
| Current Liabilities | 4,66 M | — | — | — | 2,93 M |
{"event":"ticker_viewed","properties":{"ticker":"CRVO","listing_kind":"stock","pathname":"/stocks/crvo","exchange":"Nasdaq","country":"US"}}